Select Page

Health Canada has granted BeiGene approval for BRUKINSA (Zanubrutinib) to treat mantle cell lymphoma (MCL) in adults who have already received at least one other prior treatment. As global, science-driven biotechnology company, BeiGene focuses on improving treatment outcomes for patients around the world. Health Canada approved BRUKINSA based on data from two single-arm clinical trials, with results indicating it had an overall response rate (ORR) of 84%. Antonella Rizza, Chief Executive Officer at Lymphoma Canada stated that, “The approval of BRUKINSA as a second line therapy is positive news for patients undergoing treatment for mantle cell lymphoma.” This is the second time BRUKINSA has been approved in Canada – in March 2021 the treatment was also approved for patients with Waldenström’s macroglobulinemia (WM).

Read more here.

More on: